Joanna Young

Joanna Young provides clients with data-driven policy analysis using her quantitative skills, modeling expertise, and knowledge of Medicare and other public health insurance programs.

Joanna creates analytical models that support analysis of the policy impact on different business lines and the overall healthcare market. Her work includes assessments of impact on covered lives and federal budgetary costs and savings associated with proposed legislative changes. She also focuses on data and policy analysis for pharmaceutical products, including the 340B Drug Pricing Program as well as market access, reimbursement, and commercialization issues.

Prior to joining Avalere, Joanna worked at Integrity Management Services, where she designed and conducted analytics in support of the Centers for Medicare & Medicaid Services' program integrity efforts to combat fraud and assure compliance in the Medicare and Medicaid programs.

Joanna has an MPP with a concentration in healthcare policy and statistics from The College of William and an MA and BA in sociology from the University of Warsaw's Institute of Applied Social Sciences in Poland.

Authored Content

As policymakers consider reforms to the Part D benefit to address rising out-of-pocket (OOP) costs by adding a maximum OOP cap, an Avalere analysis examines the types of beneficiaries mostly likely to be helped by such a policy.

New Avalere analysis finds that shifting Part B-covered rheumatoid arthritis (RA) drugs to Part D benefit would increase the share of prescriptions occurring in the catastrophic phase for impacted beneficiaries by more than 5 times.

As policymakers increasingly consider policy options to reform Medicare Part D and reduce program expenditures, an Avalere analysis examines spending across classes with various availability of brand and generic drugs.

In a new analysis, Avalere examines the implications of CMS’ potential new requirement that Part D plans place generics only on generic tiers.

New Avalere research finds high utilization of generic medications in the 6 protected drug classes under Part D.

MA plans expand coverage of supplemental benefits following administration’s policy change.

Avalere examines the effect of foundation-sponsored financial assistance on out-of-pocket costs and federal spending.

Rural hospitals will see an average 2.7% net increase of Part B payments.

Analysis also finds that 62% of impacted facilities will experience less than a 5% reduction in Medicare Part B revenue due to the drug cuts, but 6% of applicable hospitals will experience cuts greater than 10%.

According to a new analysis by Avalere, total profit margins for freestanding skilled nursing facilities (SNFs) in Pennsylvania decreased 28 percent between fiscal years (FY) 2007 and 2014, from 3.2 percent to 2.3 percent.

A new analysis by Avalere Health estimates that three proposed policy changes to expand Medicare reimbursement of telehealth and remote patient monitoring (RPM) would collectively decrease federal spending by $1.8 billion between FY2017 and FY2026.